• In July 2026, Insperity reported second-quarter 2026 results showing sales of US$1,686 million and a quarterly net income of US$4 million, alongside updated guidance that now spans from a loss to a profit for both the third quarter and full year.
• The company also disclosed that it repurchased 172,000 shares for US$4 million in the second quarter, capping a long-running buyback program that has retired more than 40.46 million shares since 1999, which may influence how investors think about capital allocation against a backdrop of softer year-to-date earnings.
• With quarterly profitability returning but full-year guidance widened to include potential losses, we’ll examine how this affects Insperity’s investment narrative.

Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.

Insperity Investment Narrative Recap

To own Insperity, you need to believe its HR outsourcing model and emerging HRScale platform can offset pressure from volatile benefits costs and a sensitive small business customer base. The latest update, with Q2 profitability but a wide range for Q3 and full year outcomes, keeps the main near term catalyst centered on stabilizing margins while the key risk remains that healthcare and benefits inflation could still overwhelm pricing and plan design efforts. The new guidance does not materially change that balance.

The completion of Insperity’s long running buyback program, with 172,000 shares repurchased in Q2 for US$4 million and more than 40.46 million shares retired since 1999, is the most relevant backdrop to this earnings release. It frames how management has historically balanced returning capital with funding investments such as HRScale and broader technology upgrades, which now sit at the heart of the potential earnings recovery investors are watching for.

Yet while HRScale could support that recovery, investors should also be aware that persistent healthcare cost pressures may still...

Insperity's narrative projects $7.6 billion revenue and $141.9 million earnings by 2029.

Uncover how Insperity's forecasts yield a $43.75 fair value, a 18% downside to its current price.

Exploring Other Perspectives

The lowest analysts were already cautious, assuming revenue of about US$8.2 billion and earnings near US$95.6 million by 2028, and this Q2 update may push you to revisit whether those more pessimistic assumptions about HRScale adoption and benefits cost pressures still feel too harsh or perhaps closer to your own comfort zone.

Explore 4 other fair value estimates on Insperity - why the stock might be worth 36% less than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Insperity research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Insperity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Insperity's overall financial health at a glance.

Contemplating Other Strategies?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• Find 49 companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.